Item 5.07 Submission of Matters to a Vote of Security Holders. On June 5, 2026, Arcturus Therapeutics Holdings Inc. (the “ Company”) held its 2026 annual meeting of stockholders (the “ Meeting”). The total number of shares of common stock, par value $0.001 per share, entitled to vote at the Meeting was 28,423,069 and there were present at the Meeting, in person or by proxy, 21,435,189 shares, which constituted a quorum for the Meeting. At the Meeting, the stockholders voted on the following proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the SEC on April 24, 2026 (the “ Proxy Statement”): (1) To elect Dr. Peter Farrell, Joseph E. Payne, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz, Dr. John Markels, and Dr. Moncef Slaoui to the Board of Directors, to serve until the Company’s annual meeting of stockholders; (2) To approve, on a non-binding advisory basis, the resolution approving named executive officer compensation; and (3) To ratify the appointment of Deloitte & Touche LLP (“ Deloitte”), as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final results of the stockholder votes at the Meeting are set forth below: Proposal No. 1